Zhitong Finance App learned that on August 21, 2026, Hang Seng Index Company announced the results of the Hang Seng Index series of quarterly reviews up to June 30, 2026. Among them, True Health Care (02697) was included in the Hang Seng Composite Index. Changes in the Hang Seng Composite Index will be implemented after the market closes on September 4 (Friday) and will take effect on September 7 (Monday). At that time, the Shanghai and Shenzhen Stock Exchange will adjust the scope of investment targets of Hong Kong Stock Connect accordingly. True Healthcare may be transferred to the Hong Kong Stock Connect because it meets a range of standards including market value, liquidity, etc.
Recently, the Yunnan Provincial Government Procurement Network issued a transaction notice. The organ room temperature perfusion system (model TH-LSLIV100 (SR)) supplied by True Health Medical received purchase confirmation from Yunnan Agricultural University's “Yunnan Key Laboratory of Small Pig Gene Editing and Xenologous Organ Transplantation Research Equipment Procurement Project No. 2026-73”.
Judging from the product capabilities, the TH-LSLIV100 (SR) launched by True Health this time is not a single organ storage device in the traditional sense, but an integrated scientific research platform formed around room temperature perfusion, sensor monitoring, and lung ventilation requirements of multiple organs. The official implementation of this procurement project means that the product has completed the engineering qualification and prototype verification stage, and has an engineering foundation extending from scientific research scenarios to pre-clinical research and even future clinical applications. For the company, this is not only a one-time supply of equipment, but also a key point in the transformation of the room temperature multi-organ infusion platform from R&D to industrialization.